Exagen Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a XGN research report →
Companywww.exagen.com
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
- CEO
- John Aballi
- IPO
- 2019
- Employees
- 209
- HQ
- Vista, CA, US
Price Chart
Valuation
- Market Cap
- $92.53M
- P/E
- -4.53
- P/S
- 1.35
- P/B
- 6.33
- EV/EBITDA
- -4.77
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 58.32%
- Op Margin
- -20.65%
- Net Margin
- -29.49%
- ROE
- -113.53%
- ROIC
- -33.34%
Growth & Income
- Revenue
- $66.58M · 19.65%
- Net Income
- $-19,951,000 · -31.99%
- EPS
- $-0.93 · -12.05%
- Op Income
- $-14,070,000
- FCF YoY
- -3.42%
Performance & Tape
- 52W High
- $12.23
- 52W Low
- $2.59
- 50D MA
- $3.06
- 200D MA
- $6.62
- Beta
- 1.81
- Avg Volume
- 381.16K
Get TickerSpark's AI analysis on XGN
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 17, 25 | McKhann Chas | other | 0 |
| Mar 16, 26 | McKhann Chas | other | 0 |
| Feb 27, 26 | Black Jeffrey G. | other | 1,511 |
| Mar 12, 26 | Black Jeffrey G. | other | 75,000 |
| Mar 12, 26 | Black Jeffrey G. | other | 50,000 |
| Mar 12, 26 | ABALLI JOHN | other | 150,000 |
| Mar 12, 26 | ABALLI JOHN | other | 100,000 |
| Mar 3, 26 | ABALLI JOHN | other | 2,535 |
| Mar 3, 26 | ABALLI JOHN | sell | 15,698 |
| Feb 24, 26 | ABALLI JOHN | sell | 11,430 |
Our XGN Coverage
We haven't published any research on XGN yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate XGN Report →